RA0412

antibody from Oursmab

Targeting: ILDR2 C1orf32

Western blot (Data presented on provider website)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0412

Provider

Oursmab

Product name

Bapotulimab (Biosimilar Reference Antibody) (ILDR2)

Antibody type

Monoclonal

Description

Bapotulimab (BAY-1905254) is a mouse/human cross-reactive monoclonal antibody of the IgG2 isotype. It is classified as an immune checkpoint inhibitor being developed for cancer immunotherapy. Its mechanism of action involves blocking the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). By binding to and inhibiting ILDR2, which normally exerts an immunosuppressive effect, Bapotulimab aims to lift the brake on T-cell activities. This leads to the induction of a cytotoxic T-lymphocyte (CTL) response against tumor cells, thereby restoring and enhancing the anti-tumor immune response. It has been investigated in Phase I clinical trials for advanced solid tumors, including in combination with PD-1 inhibitors like pembrolizumab.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.